Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dorzolamide + timolol + brimonidine
- Development stage
- Phase 3
- Lead developer
- Laboratorios Sophia
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
**Dorzolamide + timolol + brimonidine** is a fixed-dose ophthalmic ocular-hypotensive combination used to lower intraocular pressure in primary open-angle glaucoma and ocular hypertension. Dorzolamide inhibits carbonic anhydrase in the ciliary body to reduce aqueous-humor production; timolol nonselectively blocks beta-adrenergic receptors to further reduce aqueous-humor formation; and brimonidine is an alpha-2 adrenergic agonist that decreases aqueous production and increases uveoscleral outflow. Laboratorios Sophia developed preserved and preservative-free formulations, including Krytantek Ofteno and the preservative-free development formulation PRO-122. ([cdn.clinicaltrials.gov](https://cdn.clinicaltrials.gov/large-docs/13/NCT03257813/Prot_SAP_000.pdf))
- Brand names
- Krytantek OftenoKrytantek Ofteno PF
- Other names
- brimonidine + dorzolamide + timololdorzolamide + timolol + brimonidinetimolol + brimonidine + dorzolamide
02
Targets
ADRB1 (β1)CA (Carbonic anhydrase)ADRA2A (α2A)
Beyond the preview
Go deeper on dorzolamide + timolol + brimonidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dorzolamide + timolol + brimonidine.